Table 2.
Autoantibody Analysis at Baseline in the Efficacy Population (n = 38)
| Autoantibody Assays | n (%) |
|---|---|
| Anti-SOX2 | |
| Positive | 9 (23.7) |
| Negative | 29 (76.3) |
| Not performed/missing | 0 |
| Anti-Hu | |
| Positive | 6 (15.8) |
| Negative | 32 (84.2) |
| Not performed/missing | 0 |
| Anti-Yo | |
| Positive | 2 (6.5) |
| Negative | 29 (93.5) |
| Not performed/missing | 7 |
| Anti-VGCCA | |
| Positive | 0 |
| Negative | 24 (100) |
| Not performed/missing | 14 |
| Anti-VGPCA | |
| Positive | 2 (8.3) |
| Negative | 22 (91.7) |
| Not performed/missing | 14 |
| Thyroid peroxidase | |
| Positive | 4 (16.0) |
| Negative | 21 (84.0) |
| Not performed/missing | 13 |
| Rheumatoid factors | |
| Positive | 3 (12.5) |
| Negative | 21 (87.5) |
| Not performed/missing | 14 |
| Antimuscle antibodies | |
| Positive | 0 |
| Negative | 33 (100) |
| Not performed/missing | 5 |
| ANA | |
| Positive | 10 (28.6) |
| Negative | 25 (71.4) |
| Not performed/missing | 3 |
| ANCA | |
| Positive | 2 (8.3) |
| Negative | 22 (91.7) |
| Not performed/missing | 14 |
Note: Denominator is nonmissing data for the analysis population for each test performed.
SOX2, SRY-box 2; anti-Hu, anti-human; anti-Yo, purkinje cell cytoplasmic antibody type 1; VGCCA, voltage-gated calcium channel antibody; VGPCA, anti-voltage gated potassium channel antibody; ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody.